Sickle cell disease
Vertex Gears Up for exa-cel Launch, Acknowledges Vast Opportunity with Cautious Outlook
Anika Sharma
After a prolonged journey in development, the first CRISPR-based gene editing therapy has recently received approval from an FDA advisory ...
FDA Panel Approves First CRISPR Therapy After Rigorous Safety Evaluations
Anika Sharma
The FDA advisory committee has expressed satisfaction with the evaluation of potential off-target effects conducted by CRISPR Therapeutics and Vertex ...
2seventy Bio slashes 176 jobs and looks for new CEO after cell therapy setback
Anika Sharma
2seventy bio, the spinoff from bluebird bio, is undergoing significant changes under the leadership of CEO Nick Leschly. The company ...
Fulcrum’s Sickle Cell Disease Program Resumes as FDA Lifts 6-Month Hold
Anika Sharma
Fulcrum Therapeutics’ ambitions in the realm of sickle cell disease (SCD) have been revitalised after a six-month hiatus. The FDA ...
FDA Grants Priority Review for Bluebird Bio’s Sickle Cell Treatment
SG Tylor
Source – bluebird bio On June 21, 2023, the US Food and Drug Administration (FDA) accepted the Biologics Licence Application ...
